Optimized preparation and preliminary evaluation of [64Cu]-DOTA- trastuzumab for targeting ErbB2/Neu expression

Journal of Radioanalytical and Nuclear Chemistry

Volumn 295, Issue 2, 2013, Pages 1261-1271

  Alirezapour, Behrooz ^b   Jalilian, Amir Reza ^a   Rasaee, Mohammad Javad ^b   Rajabifar, Saeed ^a   Yavari, Kamal ^a   Kamalidehghan, Mohsen ^a   Bolourinovin, Fatemeh ^a   Aslani, Gholamreza ^a  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

64Cu; Biodistribution; Conjugation; Radiolabeling; Trastuzumab

Indexed keywords

COPPER 64; COPPER CHLORIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GADOTERIC ACID; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GEL ELECTROPHORESIS; IMMUNOREACTIVITY; IN VITRO STUDY; INTERNALIZATION; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MOLECULAR IMAGING; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; SKIN; SPECTROPHOTOMETRY; SPLEEN; THIN LAYER CHROMATOGRAPHY; TISSUE DISTRIBUTION; WILD TYPE;

EID: 84876288947     PISSN: 02365731     EISSN: 15882780     Source Type: Journal    
DOI: 10.1007/s10967-012-1939-z     Document Type: Article

References (35)

1. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516
2. Pauletti G, Dandekar S, Rong H et al (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664
3. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
4. Leonard DS, Hill ADK, Kelly L, Dijkstra B, McDermott E, Higgins NJO (2002) Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 89:262-271
5. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ et al (2005) Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 32:51-58
6. 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm 18:355-363
7. 111In labeled Herceptin. Nucl Med Biol 29:599-606
8. 76Br]undecahydro-bromo-7, 8-dicarba-nido-undecaborate(1-) ion. Nucl Med Biol 31:425-433
9. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50(6):974-981
10. Firestone RB, Shirley VS, Baglin CM, Zipkin J (1996) Table of isotopes. 8th edn. Wiley, New York, p 1447
11. Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP et al (2003) Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid for radiolabeling proteins. Nucl Med Biol 30:581-595
12. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 57:841-847
13. 2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 30:101-109
14. 212Pb. Nucl Med Biol 27:93-100
15. 67Cu process. Appl Radiat Isot 59:343-351
16. Ziegler JF, Biersack JP, Littmark U (2000) The stopping and range of ions in matter (SRIM Code). Version 2000 XX
17. Weisberg AM (1990) Gold plating, 9th edn. ASM International, Metals Park, pp 247-250
18. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW (1992) Spectrophotometric method for the determination of a bifunctional dtpa ligand in DTPA-monoclonal antibody conjugates. Bioconjugate Chem 3:342-345
19. Laemmli UK (1970) Cleavage of structural proteins during assembly of the head of the bacteriophage T4. Nat (Lond) 227:680-685
20. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactivity fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77-89
21. Matzku S, Moldenhauer G, Kalthoff H, Canevari S, Colanaghi M, Schuhmacher J et al (1990) Antibody transport and internalization into tumors. Br J Cancer 62:1-5
22. Singh B (1996) Nuclear data sheets for A = 64. Nucl Data Sheets 78:395-546
23. Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP et al (1995) Effect of the extent of chelate substitution to the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 55:878-884
24. Zimmermann K, Grunberg J, Honer M, Ametamey S, Schubiger PA, Novak-Hofer I (2003) Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl Med Biol 30:417-427
25. Spiridon CI, Sarah Guinn S, Vitetta ES (2004) A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 10:3542-3548
26. 57Co. Int J Radiat Appl Instrum 13:363-368
27. 64Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability. Bioconjug Chem 23(5):1029-1039
28. 64Cu-BAT-2IT- 1A3. Cancer Biother Radiopharm 16:483-494
29. 111In-labeled trastuzumab (Herceptin) Modified with nuclear localization sequences (NLS): an auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 48(8):1358-1368
30. Bass LA, Wang M, Welch MJ, Anderson CJ (2000) In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 11:527-532
31. Mandal AK, Yang Y, Kertesz TM, Arguello JM (2004) Identification of the transmembrane metal binding site in Cu+ transporting PIB-type ATPases. J Biol Chem 279:54802-54807
32. Catherine FF, Craig JR, Darell DB, Michael RZ (2000) Radioiodination via d-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing antiepidermal growth factor receptor variant III monoclonal antibody. Cancer Res 60:4453
33. Jones-Wilson TM, Deal KA, Anderson CJ, McCarthy DW, Kovacs Z, Motekaitis RJ et al (1998) The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 25:523-530
34. Kokai Y, Cohen JA, Drebin JA, Greene MI (1987) Stage- and tissue-specific expression of the neu oncogene in rat development. Dev Biol 84:8498-8501
35. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML (2000) Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 165:5112-5121